"For Congress, they should focus attention on creating a pathway for FDA approval of generic biologics that creates comparable savings and on removing legal and regulatory obstacles that retard the introduction of generics," he added.
Also, Precht said, there are no signs of slower growth in price increases for brand name drugs. "In addition, the sharp rise in Part D premiums for 2009 shows that the period of relatively slow growth in Part D costs (2006-2007 in this report) is over," he said.
For more on health-care costs in the United States, visit the Kaiser Family Foundation.
Copyright © 2011 HealthDay. All rights reserved.